Citations

Clear

71 citation(s) found for "Flick, M".

Summary of the Update Session on Clinical Neurotoxicity Studies
Pinyavat, Teeda , Flick, Randall P., McCann, Mary Ellen , Andropoulos, Dean B. , Hu, Danquig, Sall, Jeffrey W. , Spann, Marisa N. , Ing, Caleb , Warner, David O.

Mayo Clinic

Journal of Neurosurgical Anesthesiology | September 3, 2016 | Volume: 28 | Issue: 4 | Pages: 356-360

10.1097/ana.0000000000000347 | PMID 27768673 Get It

During the Fifth Pediatric Anesthesia Neurodevelopmental Assessment Symposium, experts and stakeholders met to present and discuss recent advances made in the study of neurodevelopmental outcomes after exposure to anesthetic drugs in infants and children. This article summarizes the update of 5 ongoing clinical studies: General Anesthesia compared to Spinal Anesthesia, Toxicity of Remifentanil and Dexmedetomidine, Mayo Anesthesia Safety in Kids, the University of California San Francisco human cohort study, and Columbia University Medical Center Neonatal Magnetic Resonance Imaging study. The purpose of this summary is to discuss the contributions and limitations of these studies, how they fit into the published literature, and what questions remain to be answered.
An automated real‐time method for the detection of patients at risk for malignant hyperthermia
Gleich, Stephen J. , Strupp, Kim M. , Wilder, Robert T., Kor, Daryl J. , Flick, Randall P., Flick, Randall

Mayo Clinic

Pediatric Anesthesia | June 27, 2016 | Volume: 26 | Issue: 9 | Pages: 876-882

10.1111/pan.12954 | PMID 27346873 Get It

SummaryBackgroundMalignant hyperthermia (MH) is a rare anesthetic pharmacogenetic disorder that can be difficult to detect in its earliest phases. Prompt treatment is known to improve outcomes. The modern anesthesia information management systems (AIMS) collect enormous amounts of data. However, data lack context and are not able to provide real‐time guidance. Utilizing our AIMS, we developed the capacity to incorporate decision support.AimsWe describe the creation and evaluation of a real‐time detection tool for MH.MethodsCases of MH from 2003 to 2013 were retrospectively reviewed to confirm the diagnosis of MH and to calculate a MH clinical grading scale score. The index cases were utilized to develop four electronic data Rules, based on endtidal CO2 (ETCO2) and temperature criteria. The Rules were then applied retrospectively to the index cases and to a full cohort of general operating room (OR) patients from January 2012 to June 2012. If criteria for possible MH was met, the detection tool generated an alert on the monitor at the patient's bedside.ResultsWe identified seven patients with confirmed MH with MH Scores ranging from 28 to 70. Using four data Rules, all of our seven index cases were captured and generated an appropriate alert. Median time from MH computer alert time to dantrolene administration time among our index cases was 23 min (IQR 17–77). There were 938 false‐positive alerts for possible MH (1.8%) when the Rules were applied to a general OR cohort of 51 579 total cases from January 2012 to June 2012.ConclusionsWe demonstrated a real‐time MH detection tool based on established physiologic criteria that is sensitive enough to capture cases suspicious for MH, while limiting false positives to prevent alarm fatigue. This has the potential to notify the provider of possible MH such that treatment may be rapidly initiated.
Effects of anesthesia and surgery on the developing brain: problem solved?
Flick, Randall P., Warner, David O.

Mayo Clinic

Pediatric Anesthesia | March 5, 2015 | Volume: 25 | Issue: 4 | Pages: 435-436

10.1111/pan.12624 | PMID 25752789 Get It

Regionalization of pediatric anesthesia care: has the time come?
Harrison, Tracy E. , Engelhardt, Thomas , Flick, Randall P., Macfarlane, Fiona R.

Mayo Clinic

Pediatric Anesthesia | August 4, 2014 | Volume: 24 | Issue: 9 | Pages: 897-898

10.1111/pan.12432 | PMID 25092445 Get It

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
Grothey, Axel, Flick, E. Dawn, Cohn, Allen Lee, Bekaii‐Saab, Tanios , Bendell, Johanna C. , Kozloff, Mark, Roach, Nancy, Mun, Yong, Fish, Susan, Hurwitz, Herbert I. , Bekaii-Saab, Tanios S

Mayo Clinic

Pharmacoepidemiology and Drug Safety | May 16, 2014 | Volume: 23 | Issue: 7 | Pages: 726-734

10.1002/pds.3633 | PMID 24830357 Get It

ABSTRACTPurposeThis analysis from Avastin® Registries: Investigation of Effectiveness and Safety (ARIES) examined the association between exposure to bevacizumab after disease progression (PD) and postprogression survival (PPS) in bevacizumab‐exposed metastatic colorectal cancer (mCRC) through the application of time‐dependent and time‐fixed analytical methods.MethodsPatients with mCRC who were treated with first‐line bevacizumab and who survived first PD (PD1) were included. A time‐dependent Cox regression model was fitted to assess the effect of cumulative bevacizumab exposure on PPS, while controlling for potential confounders. In addition to support findings from previous studies, a modified intent‐to‐treat (mITT) analysis compared PPS in patients who received bevacizumab beyond disease progression (BBP) with those who did not (No‐BBP).ResultsOf 1550 patients, 1199 survived PD1 and had a median PPS of 13.4 months. Cumulative bevacizumab exposure was associated with improved PPS (p = 0.0040). After adjusting for confounders, the hazard ratios (HRs) for PPS decreased, on average, by 1.2% (range, 1.1–1.3%) with each additional dose of bevacizumab. In the mITT analysis, the median PPS for BBP (n = 438) was 14.4 months vs 10.6 months with for No‐BBP (n = 667). BBP was found to be independently associated with longer PPS in a multivariable Cox regression analysis (HR, 0.84; 95% confidence interval, 0.73–0.97). Protocol‐specified adverse events suspected to be associated with bevacizumab occurred in 13.0% of patients with BBP.ConclusionThis analysis supports the observation that bevacizumab exposure after PD1 is associated with longer PPS in mCRC. Copyright © 2014 John Wiley & Sons, Ltd.
Anesthetic-related Neurotoxicity in the Young and Outcome Measures
Flick, Randall P., Nemergut, Michael E. , Christensen, Kaare , Hansen, Tom G. , Christensen, Kaare

Mayo Clinic

Anesthesiology | April 4, 2014 | Volume: 120 | Issue: 6 | Pages: 1303-1305

10.1097/aln.0000000000000249 | PMID 24705443 Get It

Anesthetic neurotoxicity: what to tell the parents?
Nemergut, Michael E. , Aganga, Devon O. , Flick, Randall P.

Mayo Clinic

Pediatric Anesthesia | November 27, 2013 | Volume: 24 | Issue: 1 | Pages: 120-126

10.1111/pan.12325 | PMID 24283891 Get It

SummaryOver the past decade, numerous preclinical and retrospective human studies have reported that the provision of anesthetic and sedative agents to infants and children may be associated with adverse neurodevelopmental outcomes. These data have gained widespread attention from professional and regulatory agencies, including the public at large. As such, pediatric anesthesiologists are being increasingly questioned by parents about the risks of anesthetic agents on their children's neurocognitive development. To impart a framework from which anesthesiologists may address the apprehensions of parents who actively bring up this issue, we review the data supporting anesthetic neurotoxicity and discuss its strengths and limitations. As many parents are not yet aware and do not actively raise these concerns, we also discuss whether such a conversation should be undertaken as a part of the consent process.
Standardizing Central Line Safety
Mueller, Jeff T., Wright, Alan J. , Fedraw, Leslie A., Murad, M. Hassan , Brown, Daniel R. , Thompson, Kristine M., Flick, Randall P., Seville, Maria Teresa , Huskins, W. Charles , Murad, M Hassan , Huskins, W Charles

Mayo Clinic

American Journal of Medical Quality | July 24, 2013 | Volume: 29 | Issue: 3 | Pages: 191-199

10.1177/1062860613494752 | PMID 23880777 Get It

Response to: the Fontan patient in the non cardiac setting
Mauermann, William J., Flick, Randall P., Rabbitts, Jennifer A.

Mayo Clinic

Pediatric Anesthesia | July 4, 2013 | Volume: 23 | Issue: 8 | Pages: 763-763

10.1111/pan.12215 | PMID 23822184 Get It

Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
Bendell, Johanna C. , Bekaii‐Saab, Tanios , Cohn, Allen Lee, Hurwitz, Herbert I. , Kozloff, M., Tezcan, Haluk, Roach, Nancy, Mun, Yong, Fish, Susan, Flick, E. Dawn, Dalal, Darshan, Grothey, Axel, Bekaii-Saab, Tanios S

Mayo Clinic

The Oncologist | September 27, 2012 | Volume: 17 | Issue: 12 | Pages: 1486-1495

10.1634/theoncologist.2012-0190 | PMID 23015662 Get It

Abstract Background. The Avastin® Registry: Investigation of Effectiveness and Safety (ARIES) study is a prospective, community-based observational cohort study that evaluated the effectiveness and safety of first-line treatment patterns, assessing the impact of chemotherapy choice and treatment duration. Methods. The ARIES study enrolled patients with metastatic colorectal cancer (mCRC) receiving first-line chemotherapy with bevacizumab and followed them longitudinally. The protocol did not specify treatment regimens or assessments. Analyses included all patients who initiated bevacizumab in combination with either first-line oxaliplatin with infusional 5-fluorouracil and leucovorin (FOLFOX) or irinotecan with infusional 5-fluorouracil and leucovorin (FOLFIRI). Progression-free survival (PFS) and overall survival (OS) times were estimated using Kaplan–Meier methods. Hazard ratios (HRs) were estimated with multivariate Cox regression analysis, adjusting for potential confounding factors. Results. In total, 1,550 patients with first-line mCRC were enrolled (median follow-up, 21 months) and most received FOLFOX–bevacizumab (n = 968) or FOLFIRI–bevacizumab (n = 243) as first-line therapy. The baseline characteristics and median treatment duration were generally similar between subgroups. There were no significant differences in the median PFS (10.3 months vs. 10.2 months) or OS (23.7 months vs. 25.5 months) time between the FOLFOX–bevacizumab and FOLFIRI–bevacizumab subgroups, respectively, by unadjusted analyses. Multivariate analyses showed FOLFIRI–bevacizumab resulted in a similar PFS (HR, 1.03; 95% confidence interval [CI], 0.88–1.21) and OS (HR, 0.95; 95% CI, 0.78–1.16) outcome as with FOLFOX–bevacizumab. The incidence proportions of bevacizumab-associated adverse events were similar for FOLFOX- and FOLFIRI-based therapies. Conclusions. In first-line mCRC patients, the FOLFOX–bevacizumab and FOLFIRI–bevacizumab regimens were associated with similar treatment patterns and clinical outcomes.